1. Home
  2. DAVA vs SLN Comparison

DAVA vs SLN Comparison

Compare DAVA & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Endava plc (each representing one)

DAVA

Endava plc (each representing one)

HOLD

Current Price

$6.74

Market Cap

356.2M

Sector

Technology

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.96

Market Cap

318.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAVA
SLN
Founded
2000
1994
Country
United Kingdom
United Kingdom
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
356.2M
318.4M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
DAVA
SLN
Price
$6.74
$6.96
Analyst Decision
Buy
Buy
Analyst Count
7
6
Target Price
$16.33
$39.67
AVG Volume (30 Days)
1.6M
280.4K
Earning Date
11-11-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
58.26
N/A
EPS
0.25
N/A
Revenue
$1,015,391,026.00
$25,830,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.62
N/A
P/E Ratio
$26.52
N/A
Revenue Growth
1.07
40.39
52 Week Low
$6.02
$1.97
52 Week High
$34.94
$8.88

Technical Indicators

Market Signals
Indicator
DAVA
SLN
Relative Strength Index (RSI) 42.41 56.90
Support Level $6.02 $5.98
Resistance Level $6.54 $6.88
Average True Range (ATR) 0.26 0.52
MACD 0.10 0.02
Stochastic Oscillator 80.12 71.63

Price Performance

Historical Comparison
DAVA
SLN

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: